CORCEPT THERAPEUTICS INC (CORT)
About CORCEPT THERAPEUTICS INC
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $761.4M
- Net income
- $99.7M
- Total assets
- $836.7M
- Market cap
- $7.8B
- Gross margin
- 98.4%
- Operating margin
- 20.3%
- Net margin
- 20.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $675.0M
- Cost of revenue
- $10.9M
- Gross profit
- $664.2M
- Operating expenses
- $527.2M
- Operating income
- $137.0M
- Income tax
- $20.3M
- Net income
- $141.2M
- EPS (basic)
- $1.35
- EPS (diluted)
- $1.23
Balance sheet
- Total assets
- $840.6M
- Current assets
- $471.6M
- Total liabilities
- $161.0M
- Current liabilities
- $140.8M
- Shareholders’ equity
- $679.6M
Cash flow
- Operating cash flow
- $198.1M
- Investing cash flow
- -$177.6M
- Financing cash flow
- -$28.3M
- Net cash flow
- -$7.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $7.8B
- P/E ratio
- 77.5
- EPS (diluted)
- $1.23
- Shares outstanding
- 81.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 14, 2004
Corcept Therapeutics Inc (CORT) Stock Price
- Profitable — net income of $99.7M in FY2025.
- Revenue grew 91% from FY2020 to FY2024.
- Gross margin of 98.4%, net margin 20.9%.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 77.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review CORCEPT THERAPEUTICS INC.
Write a review
News about CORCEPT THERAPEUTICS INC
News & sentiment via Polygon.io
Corcept Therapeutics Inc: frequently asked questions
Is Corcept Therapeutics Inc an American company?
Yes — Corcept Therapeutics Inc is an American company headquartered in Redwood City, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Corcept Therapeutics Inc headquartered?
Corcept Therapeutics Inc is headquartered in Redwood City, California, United States.
Is Corcept Therapeutics Inc publicly traded?
Yes — Corcept Therapeutics Inc is a publicly traded company. Its stock trades under the ticker symbol CORT on the NASDAQ.
What does Corcept Therapeutics Inc do?
Corcept Therapeutics Inc is an American Pharmaceuticals company in the Health & Beauty sector.
